Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
- Asset transfer furthers Takeda’s global strategy to focus on five key business areas
- Takeda will continue to manufacture and supply products to Teijin Pharma, providing uninterrupted access to patients